Lexaria Bioscience (LEXX) EBT Margin (2017 - 2026)
Lexaria Bioscience (LEXX) posted EBT Margin of 7250.67% for Q1 2026, down 369.7% sequentially from 1543.67% in Q3 2025, and down 568919.0% YoY from N/an in Q1 2025.
Lexaria Bioscience (LEXX) EBT Margin (2017 - 2026) Analysis & Trends
Lexaria Bioscience has reported EBT Margin for 10 years, with the latest figure at 7250.67% in Q1 2026.
- Quarterly EBT Margin fell 568919.0% year-over-year to 7250.67% in Q1 2026, while the trailing twelve-month figure through May 2026 was 3981.86% (down 213241.0% YoY) and the FY2025 annual result came in at 3582.57%, down 3510.0% from the prior year.
- EBT Margin eased to 7250.67% in Q1 2026 per LEXX's latest filing, from 1543.67% in the prior quarter.
- Over five years, EBT Margin peaked at 673.46% in Q3 2022 and troughed at 7250.67% in Q1 2026.
- A 5-year average of 2796.24% and a median of 2328.07% in 2022 frame the typical range for EBT Margin.
- The sharpest annual moves came in 2022 and 2026: EBT Margin soared 1327100 bps in 2022, then tumbled 568919 bps in 2026.
- Over 5 years, EBT Margin stood at 1782.16% in 2022, then surged by 56 bps to 778.6% in 2023, then slumped by 89 bps to 1471.61% in 2024, then fell by 5 bps to 1543.67% in 2025, then slumped by 370 bps to 7250.67% in 2026.
- According to Business Quant data, EBT Margin over the past three periods registered 7250.67%, 1543.67%, and 2178.51% for Q1 2026, Q3 2025, and Q2 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.57 Bn | 131.72 Bn | 2.84 Bn | 41.75% |
| 2 | Regeneron Pharmaceuticals | 86.71 Bn | 78.72 Bn | 3.93 Bn | 35.61% |
| 3 | Argenx Se | 65.44 Bn | 60.25 Bn | 1.37 Bn | 35.71% |
| 4 | Moderna | 60.06 Bn | 54.93 Bn | 52.00 Mn | -528.97% |
| 5 | BeOne Medicines | 42.16 Bn | 37.06 Bn | 1.53 Bn | 18.33% |
| 6 | Alnylam Pharmaceuticals | 31.89 Bn | 28.58 Bn | 992.69 Mn | 13.77% |
| 7 | BioNTech SE | 28.11 Bn | 9.72 Bn | 668.28 Mn | -25.06% |
| 8 | Insmed | 27.59 Bn | 26.43 Bn | 358.27 Mn | -2.67% |
| 9 | Royalty Pharma | 27.33 Bn | 26.49 Bn | - | 12.09% |
| 10 | Lexaria Bioscience | 10.14 Mn | 6.52 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Feb 28, 2026 | -7,250.67% |
| Aug 31, 2025 | -1,543.67% |
| May 31, 2025 | -2,178.51% |
| Feb 28, 2025 | -1,561.48% |
| Nov 30, 2024 | -1,471.61% |
| Aug 31, 2024 | -2,591.61% |
| May 31, 2024 | -3,238.67% |
| Feb 29, 2024 | -737.03% |
| Nov 30, 2023 | -778.60% |
| Aug 31, 2023 | -3,635.90% |
| May 31, 2023 | -3,089.64% |
| Feb 28, 2023 | -6,759.06% |
| Nov 30, 2022 | -1,782.16% |
| Aug 31, 2022 | -673.46% |
| May 31, 2022 | -2,477.63% |
| Feb 28, 2022 | -4,970.20% |
| Nov 30, 2021 | -15,053.16% |
| Aug 31, 2021 | -4,305.56% |
| May 31, 2021 | -1,285.62% |
| Feb 28, 2021 | -598.59% |